文献速递消化系统肿瘤

胰腺癌细胞自主Cxcl1通过中性粒细胞来源TNF维持免疫耐受回路与间质炎症

Cell-Autonomous Cxcl1 Sustains Tolerogenic Circuitries and Stromal Inflammation via Neutrophil-Derived TNF in Pancreatic Cancer.
PubMed 文献 · Cancer Discov · 2023-01-01

研究以KRAS-TP53共突变为高风险生物学模型,利用成像质谱流式在胰腺导管腺癌(PDAC)中识别细胞自主Cxcl1通过与CXCR2+中性粒细胞样髓源性抑制细胞相互作用介导空间性T细胞限制。沉默KPC细胞内在Cxcl1可重编程中性粒细胞运输与功能动态,以T细胞依赖方式克服T细胞排斥并控制肿瘤生长。中性粒细胞来源TNF经跨膜TNF-TNFR2相互作用驱动Cxcl1前馈过产、T细胞功能障碍与炎症性CAF极化,抑制TNFR2可破坏该回路并在体内提高化疗敏感性。

要点

  • KRAS-TP53共突变与PDAC免疫排斥微环境、化疗耐药和不良生存相关。
  • 细胞自主Cxcl1通过CXCR2+中性粒细胞样MDSC介导空间性T细胞限制。
  • 沉默KPC细胞内在Cxcl1以T细胞依赖方式克服T细胞排斥并控制肿瘤生长。

核心结论

  • 研究揭示癌细胞-中性粒细胞交互中情境依赖性TNF信号放大间质炎症与免疫耐受,促进PDAC治疗耐药。
  • 靶向情境依赖性TNF信号可能克服胰腺癌化疗耐药标志,提供概念框架。

研究设计与样本

  • 研究利用成像质谱流式在人类PDAC中分析KRAS-TP53共突变高风险生物学模型。
  • 在LSL-KrasG12D/+;Trp53R172H/+;Pdx-1Cre/+(KPC)细胞中沉默细胞内在Cxcl1并进行体内功能研究。
  • 机制研究聚焦中性粒细胞来源TNF及跨膜TNF-TNFR2相互作用,并在体内评估TNFR2抑制联合化疗。

主要发现

  • KRAS-TP53基因组共突变与PDAC免疫排斥微环境、化疗耐药和不良生存相关。
  • 细胞自主Cxcl1通过与CXCR2+中性粒细胞样髓源性抑制细胞相互作用介导空间性T细胞限制。
  • 沉默KPC细胞内在Cxcl1重编程中性粒细胞运输与功能动态,以T细胞依赖方式克服T细胞排斥并控制肿瘤生长。
  • 中性粒细胞来源TNF经跨膜TNF-TNFR2相互作用驱动肿瘤细胞与癌相关成纤维细胞Cxcl1前馈过产、T细胞功能障碍及炎症性CAF极化。
  • TNFR2抑制破坏该回路并在体内提高化疗敏感性。

关键数值与推荐

  • KRAS-TP53共突变与PDAC免疫排斥微环境、化疗耐药和不良生存相关。
  • 细胞自主Cxcl1通过CXCR2+中性粒细胞样髓源性抑制细胞介导空间性T细胞限制。
  • 沉默KPC细胞内在Cxcl1以T细胞依赖方式克服T细胞排斥并控制肿瘤生长。
  • 中性粒细胞来源TNF经跨膜TNF-TNFR2相互作用驱动Cxcl1前馈过产与炎症性CAF极化。
  • TNFR2抑制在体内提高化疗敏感性。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: We have shown that KRAS-TP53 genomic coalteration is associated with immune-excluded microenvironments, chemoresistance, and poor survival in pancreatic ductal adenocarcinoma (PDAC) patients. By treating KRAS-TP53 cooperativity as a model for high-risk biology, we now identify cell-autonomous Cxcl1 as a key mediator of spatial T-cell restriction via interactions with CXCR2+ neutrophilic myeloid-derived suppressor cells in human PDAC using imaging mass cytometry. Silencing of cell-intrinsic Cxcl1 in LSL-KrasG12D/+;Trp53R172H/+;Pdx-1Cre/+(KPC) cells reprograms the trafficking and functional dynamics of neutrophils to overcome T-cell exclusion and controls tumor growth in a T cell-dependent manner. Mechanistically, neutrophil-derived TNF is a central regulator of this immunologic rewiring, instigating feed-forward Cxcl1 overproduction from tumor cells and cancer-associated fibroblasts (CAF), T-cell dysfunction, and inflammatory CAF polarization via transmembrane TNF-TNFR2 interactions. TNFR2 inhibition disrupts this circuitry and improves sensitivity to chemotherapy in vivo. Our results uncover cancer cell-neutrophil cross-talk in which context-dependent TNF signaling amplifies stromal inflammation and immune tolerance to promote therapeutic resistance in PDAC. SIGNIFICANCE: By decoding connections between high-risk tumor genotypes, cell-autonomous inflammatory programs, and myeloid-enriched/T cell-excluded contexts, we identify a novel role for neutrophil-derived TNF in sustaining immunosuppression and stromal inflammation in pancreatic tumor microenvironments. This work offers a conceptual framework by which targeting context-dependent TNF signaling may overcome hallmarks of chemoresistance in pancreatic cancer. This article is highlighted in the In This Issue feature, p. 1275.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Bianchi A, De Castro Silva I, Deshpande NU, et al. Cell-Autonomous Cxcl1 Sustains Tolerogenic Circuitries and Stromal Inflammation via Neutrophil-Derived TNF in Pancreatic Cancer. Cancer Discov. 2023. PMID: 36946782. doi:10.1158/2159-8290.CD-22-1046

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。